{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:09:15Z","timestamp":1773425355866,"version":"3.50.1"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001411","name":"ICMR","doi-asserted-by":"publisher","award":["5\/13\/31\/AB\/ICRC\/2022-NCD-III"],"award-info":[{"award-number":["5\/13\/31\/AB\/ICRC\/2022-NCD-III"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alterations in genes involved in homologous recombination repair (HRR) occur in approximately 20%-25% of patients with metastatic prostate cancer and are associated with aggressive biology, poor outcomes, and potential sensitivity to poly (ADP-ribose) polymerase inhibitors (PARPi). However, frequency and variations in somatic HRR mutations in the Indian population are unknown.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed somatic HRR alterations in patients at the All India Institute of Medical Sciences, New Delhi, between 2022 and November 2024. Targeted next-generation sequencing of 15 HRR genes was performed on tumor tissue samples. Demographic and clinicopathological variables were retrieved from medical records, and their associations were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of 247 patients tested, 167 were evaluable (32.3% tissue failure due to poor DNA yield). Sixty-eight pathogenic HRR alterations were detected across 51 patients (30.5%). ATM was the most frequently altered gene (13.2%), followed by BRCA1 (5.3%), BRCA2 (4.2%), and CDK12 (4.2%). Variants of unknown significance (VUS) were detected in 12% (20) of patients. Patients with HRR alterations had higher baseline PSA values compared with the non-HRR cohort (median 150 vs 100\u2009ng\/mL, P\u2009=\u2009.012). No significant associations were observed with age, Gleason score, disease volume or risk category, or visceral metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first comprehensive dataset on the spectrum of somatic HRR mutations in Indian patients with prostate cancer. The prevalence (30.5%) was somewhat higher than the global studies, ATM was the most frequently mutated gene, followed by BRCA1, in contrast to Western and Asian cohorts, where BRCA2 predominates. These findings suggest potential population-specific variations and underscore the need for broader HRR testing to better delineate the genomic landscape of prostate cancer in Indian patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag059","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T12:41:45Z","timestamp":1771591305000},"source":"Crossref","is-referenced-by-count":0,"title":["Prevalence and spectrum of homologous recombination repair mutations in patients with metastatic prostate cancer from India"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0946-8518","authenticated-orcid":false,"given":"Hemavathi","family":"Baskarane","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishabh","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohit Kumar","family":"Divakar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amlesh","family":"Seth","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Science , New Delhi, 110029,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brusabhanu","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Urology, All India Institute of Medical Science , New Delhi, 110029,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjit Kumar","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aparna","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Kaushal","sequence":"additional","affiliation":[{"name":"Department of Pathology, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunhi Parambath","family":"Haresh","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi, 110029,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishakha","family":"Hooda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Payal","family":"Vasudeva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pranav Pratap","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishika","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanskriti","family":"Vasundhara","sequence":"additional","affiliation":[{"name":"University College of Medical Sciences , New Delhi, 110095,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1076-0428","authenticated-orcid":false,"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah , Salt Lake City, UT, 84112,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1934-8408","authenticated-orcid":false,"given":"Atul","family":"Batra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dr. BR Ambedkar Institute Rotary Cancer Hospital, All India Institute of Medical Sciences , New Delhi,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"2026031313370963700_oyag059-B1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026031313370963700_oyag059-B2","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1200\/JCO-25-00007","article-title":"Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update","volume":"43","author":"Garje","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026031313370963700_oyag059-B3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/biomedicines10030689","article-title":"Definition of castrate resistant prostate cancer: new insights","volume":"10","author":"Morote","year":"2022","journal-title":"Biomedicines"},{"key":"2026031313370963700_oyag059-B4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.path.2024.10.003","article-title":"Deciphering complexity: the molecular landscape of castration-resistant prostate cancer","volume":"18","author":"Fanelli","year":"2025","journal-title":"Surg Pathol Clin"},{"key":"2026031313370963700_oyag059-B5","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1007\/s12325-024-02844-7","article-title":"Homologous recombination repair gene mutations in prostate cancer: prevalence and clinical value","volume":"41","author":"Fan","year":"2024","journal-title":"Adv Ther"},{"key":"2026031313370963700_oyag059-B6","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"2026031313370963700_oyag059-B7","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-1178","article-title":"Association of homologous recombination repair alterations with outcomes in patients with metastatic hormone-sensitive prostate cancer","author":"Hage Chehade","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026031313370963700_oyag059-B8","doi-asserted-by":"publisher","first-page":"1162644","DOI":"10.3389\/fonc.2023.1162644","article-title":"Impact of DNA damage repair alterations on prostate cancer progression and metastasis","volume":"13","author":"Lukashchuk","year":"2023","journal-title":"Front Oncol"},{"key":"2026031313370963700_oyag059-B9","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.18632\/oncotarget.28015","article-title":"Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions","volume":"12","author":"Scott","year":"2021","journal-title":"Oncotarget"},{"key":"2026031313370963700_oyag059-B10","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.annonc.2024.01.011","article-title":"Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes","volume":"35","author":"Olmos","year":"2024","journal-title":"Ann Oncol"},{"key":"2026031313370963700_oyag059-B11","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1038\/s41391-024-00901-4","article-title":"Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)","volume":"28","author":"Armstrong","year":"2025","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026031313370963700_oyag059-B12","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1200\/JCO-24-02608","article-title":"Germline and somatic genomic testing for metastatic prostate cancer: ASCO guideline","volume":"43","author":"Yu","year":"2025","journal-title":"JCO"},{"key":"2026031313370963700_oyag059-B13","doi-asserted-by":"publisher","first-page":"4109","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","volume":"31","author":"Attard","year":"2025","journal-title":"Nat Med"},{"key":"2026031313370963700_oyag059-B14","author":"AstraZeneca","year":"2025"},{"key":"2026031313370963700_oyag059-B15","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2217\/fon-2023-0526","article-title":"TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer","volume":"20","author":"Agarwal","year":"2024","journal-title":"Future Oncol"},{"key":"2026031313370963700_oyag059-B16","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.3390\/jpm11121287","article-title":"Race-Specific genetic profiles of homologous recombination deficiency in multiple cancers","volume":"11","author":"Hsiao","year":"2021","journal-title":"J Pers Med"},{"key":"2026031313370963700_oyag059-B17","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s43018-019-0009-7","article-title":"Higher prevalence of homologous recombination deficiency in tumors from African Americans versus European Americans","volume":"1","author":"Sinha","year":"2020","journal-title":"Nat Cancer"},{"key":"2026031313370963700_oyag059-B18","doi-asserted-by":"publisher","first-page":"e2500130","DOI":"10.1200\/PO-25-00130","article-title":"Prostate-Related germline variant frequencies detected in a cohort of men with metastatic prostate cancer in Northern India","volume":"9","author":"Batra","year":"2025","journal-title":"JCO Precis Oncol."},{"key":"2026031313370963700_oyag059-B19","doi-asserted-by":"publisher","first-page":"153507","DOI":"10.1016\/j.prp.2021.153507","article-title":"Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients","volume":"224","author":"Jiang","year":"2021","journal-title":"Pathol Res Pract"},{"key":"2026031313370963700_oyag059-B20","doi-asserted-by":"publisher","first-page":"5265","DOI":"10.1002\/cam4.5333","article-title":"The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: the multi-institutional observational ZENSHIN study","volume":"12","author":"Uemura","year":"2023","journal-title":"Cancer Med"},{"key":"2026031313370963700_oyag059-B21","doi-asserted-by":"publisher","first-page":"e54086","DOI":"10.2196\/54086","article-title":"Carboplatin in patients with metastatic castration-resistant prostate cancer harboring somatic or germline homologous recombination repair gene mutations: phase II single-arm trial","volume":"13","author":"Jain","year":"2024","journal-title":"JMIR Res Protoc."},{"key":"2026031313370963700_oyag059-B22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"2026031313370963700_oyag059-B23","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"2026031313370963700_oyag059-B24","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"key":"2026031313370963700_oyag059-B25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","article-title":"Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists","volume":"19","author":"Li","year":"2017","journal-title":"J Mol Diagn"},{"key":"2026031313370963700_oyag059-B26","author":"cBioPortal","year":"2025"},{"key":"2026031313370963700_oyag059-B27","doi-asserted-by":"publisher","first-page":"1086517","DOI":"10.3389\/fonc.2023.1086517","article-title":"Somatic and germline aberrations in homologous recombination repair genes in Chinese prostate cancer patients","volume":"13","author":"Liu","year":"2023","journal-title":"Front Oncol"},{"key":"2026031313370963700_oyag059-B28","doi-asserted-by":"publisher","first-page":"v328","DOI":"10.1093\/annonc\/mdz248.004","article-title":"Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from &gt;4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study","volume":"30","author":"de Bono","year":"2019","journal-title":"Ann Oncol"},{"key":"2026031313370963700_oyag059-B29","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41391-023-00764-1","article-title":"Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases","volume":"27","author":"Shui","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2026031313370963700_oyag059-B30","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1080\/14796694.2025.2470616","article-title":"Real-world treatment patterns and genetic testing in a metastatic castration-resistant prostate cancer setting in Europe","volume":"21","author":"Castro","year":"2025","journal-title":"Future Oncol"},{"key":"2026031313370963700_oyag059-B31","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026031313370963700_oyag059-B32","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026031313370963700_oyag059-B33","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1158\/1078-0432.CCR-21-3940","article-title":"Tumor genomic testing for &gt;4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (olaparib)","volume":"28","author":"Hussain","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026031313370963700_oyag059-B34","article-title":"Factors affecting quality control (QC) failure rates in somatic breast cancer (BRCA) gene testing in castrate resistant prostate cancer: experiences from an Australian cancer care Centre","author":"O\u2019Leary","journal-title":"Asia Pac J Clin Oncol"},{"key":"2026031313370963700_oyag059-B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-020-0503-6","volume":"33","author":"Miquelestorena-Standley","year":"2020","journal-title":"Mod Pathol."},{"key":"2026031313370963700_oyag059-B36","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.3390\/cancers7030859","article-title":"Analysis of pre-analytic factors affecting the success of clinical next-generation sequencing of solid organ malignancies","volume":"7","author":"Chen","year":"2015","journal-title":"Cancers"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag059\/67077422\/oyag059.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag059\/67077422\/oyag059.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/4\/oyag059\/67077422\/oyag059.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:37:12Z","timestamp":1773423432000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag059\/8495134"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,3,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag059","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2026,2,23]]},"article-number":"oyag059"}}